FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026858056> ?p ?o ?g. }

• W2026858056 endingPage "108" @default.
• W2026858056 startingPage "99" @default.
• W2026858056 abstract "Negatively charged albumins (NCAs, with the prototypes succinylated human serum albumin (Suc-HSA) and aconitylated human serum albumin (Aco-HSA)), modified proteins with a potent anti-human immunodeficiency virus type 1 (anti-HIV-1) activity in vitro, were studied for their pharmacokinetic behaviour in mice and their in vivo anti-HIV-1 efficacy in an HIV-1 infection model in mice. In contrast to the saturation kinetics found in rats, intravenous injections of 10-300 mg/kg for both NCAs showed a linear correlation between the area under the curve (AUC) and the dose. The elimination t1/2 was 25 and 30 min for Suc-HSA and Aco-HSA, respectively. Preinjections of an excess of formaldehyde-treated albumin (Form-HSA) resulted in plasma levels that were 3- and 4-fold higher for Aco-HSA and Suc-HSA, respectively. These data indicate that elimination is at least partly (scavenger) receptor-mediated. Organ distribution studies 10 min after injection showed an accumulation in liver (Suc-HSA 17.3 +/- 6.6% of the dose; Aco-HSA 20.9 +/- 2.3%) and lungs (Suc-HSA 12.7 +/- 10.5%; Aco-HSA 16.0 +/- 13.6). Intraperitoneal injection of 300 mg/kg Suc-HSA resulted in a final bioavailability of about 0.45. Suc-HSA was also evaluated for its in vivo neutralizing capacity in a human-to-mouse chimeric model for HIV-1 infection. Intraperitoneal injections of 300 and 3 mg/kg Suc-HSA, given 15-30 min before the mice were challenged with the virus, sufficed to protect these mice against infection with the HIV-1 IIIB strain." @default.
• W2026858056 created "2016-06-24" @default.
• W2026858056 creator A5012442242 @default.
• W2026858056 creator A5013703578 @default.
• W2026858056 creator A5042423012 @default.
• W2026858056 creator A5044632676 @default.
• W2026858056 creator A5052565797 @default.
• W2026858056 creator A5057349563 @default.
• W2026858056 creator A5064633308 @default.
• W2026858056 date "1997-01-01" @default.
• W2026858056 modified "2023-09-25" @default.
• W2026858056 title "Pharmacokinetics and anti-HIV-1 efficacy of negatively charged human serum albumins in mice" @default.
• W2026858056 cites W1493790412 @default.
• W2026858056 cites W1564316553 @default.
• W2026858056 cites W1610886438 @default.
• W2026858056 cites W1775749144 @default.
• W2026858056 cites W1893651774 @default.
• W2026858056 cites W1942992519 @default.
• W2026858056 cites W1986283916 @default.
• W2026858056 cites W1988157903 @default.
• W2026858056 cites W1994040691 @default.
• W2026858056 cites W2006364222 @default.
• W2026858056 cites W2009119064 @default.
• W2026858056 cites W2023174165 @default.
• W2026858056 cites W2028784319 @default.
• W2026858056 cites W2031332141 @default.
• W2026858056 cites W2039291589 @default.
• W2026858056 cites W2050047145 @default.
• W2026858056 cites W2053687378 @default.
• W2026858056 cites W2086932183 @default.
• W2026858056 cites W2087793829 @default.
• W2026858056 cites W2094886695 @default.
• W2026858056 cites W2135960956 @default.
• W2026858056 cites W2139356960 @default.
• W2026858056 cites W2142009710 @default.
• W2026858056 cites W2143665575 @default.
• W2026858056 cites W2148698673 @default.
• W2026858056 cites W2150665783 @default.
• W2026858056 cites W2152979630 @default.
• W2026858056 cites W2154901034 @default.
• W2026858056 cites W2328896930 @default.
• W2026858056 cites W2397645082 @default.
• W2026858056 cites W2501342036 @default.
• W2026858056 cites W2579701769 @default.
• W2026858056 doi "https://doi.org/10.1016/s0166-3542(96)01005-4" @default.
• W2026858056 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9021051" @default.
• W2026858056 hasPublicationYear "1997" @default.
• W2026858056 type Work @default.
• W2026858056 sameAs 2026858056 @default.
• W2026858056 citedByCount "11" @default.
• W2026858056 crossrefType "journal-article" @default.
• W2026858056 hasAuthorship W2026858056A5012442242 @default.
• W2026858056 hasAuthorship W2026858056A5013703578 @default.
• W2026858056 hasAuthorship W2026858056A5042423012 @default.
• W2026858056 hasAuthorship W2026858056A5044632676 @default.
• W2026858056 hasAuthorship W2026858056A5052565797 @default.
• W2026858056 hasAuthorship W2026858056A5057349563 @default.
• W2026858056 hasAuthorship W2026858056A5064633308 @default.
• W2026858056 hasConcept C110121322 @default.
• W2026858056 hasConcept C112705442 @default.
• W2026858056 hasConcept C134306372 @default.
• W2026858056 hasConcept C150903083 @default.
• W2026858056 hasConcept C165616093 @default.
• W2026858056 hasConcept C181389837 @default.
• W2026858056 hasConcept C185592680 @default.
• W2026858056 hasConcept C202751555 @default.
• W2026858056 hasConcept C207001950 @default.
• W2026858056 hasConcept C2776125364 @default.
• W2026858056 hasConcept C2778597219 @default.
• W2026858056 hasConcept C2780159080 @default.
• W2026858056 hasConcept C33923547 @default.
• W2026858056 hasConcept C43617362 @default.
• W2026858056 hasConcept C55493867 @default.
• W2026858056 hasConcept C86803240 @default.
• W2026858056 hasConcept C98274493 @default.
• W2026858056 hasConceptScore W2026858056C110121322 @default.
• W2026858056 hasConceptScore W2026858056C112705442 @default.
• W2026858056 hasConceptScore W2026858056C134306372 @default.
• W2026858056 hasConceptScore W2026858056C150903083 @default.
• W2026858056 hasConceptScore W2026858056C165616093 @default.
• W2026858056 hasConceptScore W2026858056C181389837 @default.
• W2026858056 hasConceptScore W2026858056C185592680 @default.
• W2026858056 hasConceptScore W2026858056C202751555 @default.
• W2026858056 hasConceptScore W2026858056C207001950 @default.
• W2026858056 hasConceptScore W2026858056C2776125364 @default.
• W2026858056 hasConceptScore W2026858056C2778597219 @default.
• W2026858056 hasConceptScore W2026858056C2780159080 @default.
• W2026858056 hasConceptScore W2026858056C33923547 @default.
• W2026858056 hasConceptScore W2026858056C43617362 @default.
• W2026858056 hasConceptScore W2026858056C55493867 @default.
• W2026858056 hasConceptScore W2026858056C86803240 @default.
• W2026858056 hasConceptScore W2026858056C98274493 @default.
• W2026858056 hasIssue "2" @default.
• W2026858056 hasLocation W20268580561 @default.
• W2026858056 hasLocation W20268580562 @default.
• W2026858056 hasOpenAccess W2026858056 @default.
• W2026858056 hasPrimaryLocation W20268580561 @default.
• W2026858056 hasRelatedWork W1906640546 @default.

• next